Literature DB >> 9521680

Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation.

M Ploug1, S Ostergaard, L B Hansen, A Holm, K Danø.   

Abstract

Binding of urokinase-type plasminogen activator (uPA) to its cellular receptor (uPAR) renders the cell surface a favored site for plasminogen activation. Recently, a 15-mer peptide antagonist of the uPA-uPAR interaction, with an IC50 value of 10 nM, was identified using phage display technology [Goodson, R. J., Doyle, M. V., Kaufman, S. E., and Rosenberg, S. (1994) Proc. Natl. Acad. Sci. 91, 7129-7133]. In the present study, the molecular aspects of the interaction between this peptide and uPAR have been investigated. We have characterized the real-time receptor binding kinetics for the antagonist using surface plasmon resonance and identified critical residues by alanine replacements. The minimal peptide antagonist thus derived (SLNFSQYLWS) was rendered photoactivatable by replacing residues important for uPAR binding with photochemically active derivatives of phenylalanine containing either (trifluoromethyl)diazirine or benzophenone. These peptides incorporated covalently into purified soluble uPAR upon photoactivation, and this was inhibited by preincubation with receptor binding derivatives of uPA. The intact three-domain structure of uPAR was essential for efficient photoaffinity labeling. Proteolytic domain mapping using chymotrypsin revealed a specific labeling of both uPAR domain I and domains II + III dependent on the position of the photoprobe in the antagonist. On the basis of these studies, we propose the existence of a composite ligand binding site in uPAR combined of residues located in distinct structural domains. According to this model, a close spatial proximity between uPAR domain I and either domains II or III in intact uPAR is required for the assembly of this composite binding site. Since the receptor binding properties of the peptide antagonist closely mimic those of uPA itself, these two ligands presumably share coincident binding site in uPAR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9521680     DOI: 10.1021/bi972787k

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

Review 1.  Phage-displayed peptide libraries.

Authors:  M B Zwick; J Shen; J K Scott
Journal:  Curr Opin Biotechnol       Date:  1998-08       Impact factor: 9.740

2.  Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains.

Authors:  René Bager; Thomas K Kristensen; Jan K Jensen; Agnieszka Szczur; Anni Christensen; Lisbeth M Andersen; Jesper S Johansen; Niels Larsen; Erik Baatrup; Mingdong Huang; Michael Ploug; Peter A Andreasen
Journal:  J Biol Chem       Date:  2012-06-25       Impact factor: 5.157

3.  Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide.

Authors:  Paola Llinas; Marie Hélène Le Du; Henrik Gårdsvoll; Keld Danø; Michael Ploug; Bernard Gilquin; Enrico A Stura; André Ménez
Journal:  EMBO J       Date:  2005-04-07       Impact factor: 11.598

4.  Challenges for drug discovery - a case study of urokinase receptor inhibition.

Authors:  Zhuo Chen; Lin Lin; Qing Huai; Mingdong Huang
Journal:  Comb Chem High Throughput Screen       Date:  2009-12       Impact factor: 1.339

5.  Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.

Authors:  Lin Lin; Henrik Gårdsvoll; Qing Huai; Mingdong Huang; Michael Ploug
Journal:  J Biol Chem       Date:  2010-02-04       Impact factor: 5.157

6.  Synthesis and evaluation of photoreactive tetrazole amino acids.

Authors:  Yizhong Wang; Qing Lin
Journal:  Org Lett       Date:  2009-08-20       Impact factor: 6.005

7.  Mode of action of cGMP-dependent protein kinase-specific inhibitors probed by photoaffinity cross-linking mass spectrometry.

Authors:  Martijn W H Pinkse; Dirk T S Rijkers; Wolfgang R Dostmann; Albert J R Heck
Journal:  J Biol Chem       Date:  2009-04-15       Impact factor: 5.157

8.  Hydrogen atom scrambling in selectively labeled anionic peptides upon collisional activation by MALDI tandem time-of-flight mass spectrometry.

Authors:  Nicolai Bache; Kasper D Rand; Peter Roepstorff; Michael Ploug; Thomas J D Jørgensen
Journal:  J Am Soc Mass Spectrom       Date:  2008-06-11       Impact factor: 3.109

9.  Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.

Authors:  Ralf-Peter Czekay; Kathleen Aertgeerts; Scott A Curriden; David J Loskutoff
Journal:  J Cell Biol       Date:  2003-03-03       Impact factor: 10.539

10.  Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.

Authors:  C Holst-Hansen; M J Hamers; B E Johannessen; N Brünner; R W Stephens
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.